目的 通过协助临床医生诊治1例帕博丽珠单抗所致G4级皮肤毒性不良反应,探讨临床药师在免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)毒性管理中的作用。方法 临床药师通过认真分析患者的病情以及用药史,查阅国内外文献,在毒性管理、药学监护以及出院用药教育等方面提供建议。结果 临床药师提出的治疗方案被医生采纳,患者经治疗后病情明显好转。结论 临床药师利用自身的药学知识优势,可协助医生及时、准确的识别免疫性相关毒性,进行免疫毒性管理及药学监护,体现临床药师的价值。
Abstract
OBJECTIVE To explore the role of clinical pharmacists in the management of immune checkpoint inhibitors (ICIs) toxicity by assisting clinicians to diagnose and treat a case of grade 4 skin toxicity caused by pembrolizumab. METHODS The patient's condition and medication history were carefully analyzed by clinical pharmacists. Advice on toxicity management, pharmacy monitoring, and discharge medication education were provided by clinical pharmacists through consulting domestic and foreign literature. RESULTS The treatment plan proposed by the clinical pharmacist was adopted by the doctor, and the patient's condition improved significantly after treatmen. CONCLUSION Clinical pharmacists can use their own advantages in pharmacy knowledge to assist doctors in identifying immune-related toxicities in a timely and accurate manner, conducting immune toxicity management and pharmaceutical monitoring, and reflecting the value of clinical pharmacists.
关键词
免疫检查点抑制剂 /
帕博丽珠单抗 /
皮肤松解综合征 /
临床药师
{{custom_keyword}} /
Key words
immune checkpoint inhibitor /
pembrolizumab /
dermatolysis syndrome /
clinical pharmacist
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] GUANGDONG PHARMACEUTICAL ASSOCIATION. Guidelines for full-process pharmaceutical services for immune checkpoint inhibitors (2019 edition)[J]. Pharm Today (今日药学), 2020, 30(5):289-306.
[2] SI X Y, HE C X, ZHANG L, et al. Management of dermatologic toxicities related to immune checkpoint inhibitors [J]. Chin J Lung Cancer(中国肺癌杂志), 2019, 22(10):639-644.
[3] CASTILLERO F, CASTILLO-FERNANDEZ O, JIMENEZ-JIMENEZ G, et al. Cancer immunotherapy-associated hypophysitis[J]. Future Oncol, 2019, 15(27):3159-3169.
[4] HABRE M, HABRE S B, KOURIE H R. Dermatologic adverse events of checkpoint inhibitors:what an oncologist should know[J]. Immunotherapy, 2016, 8(12):1437-1446.
[5] BELUM V R, BENHURI B, POSTOW M A, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J]. Eur J Cancer, 2016, 60:12-25.
[6] SIBAUD V. Dermatologic reactions to immune checkpoint inhibitors:skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3):345-361.
[7] HSU D Y, BRIEVA J, SILVERBERG N B, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States[J]. J Am Acad Dermatol, 2017, 76(5):811-817. e4.
[8] ERGEN E N, HUGHEY L C. Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. JAMA Dermatol, 2017, 153(12):1344.
[9] ZHANG L Q, JIANG Y X, LI G, et al. A case of toxic epidermal necrolysis caused by excessive use of indomethacin suppositotr during pregancy[J]. China Pharm(中国药师), 2020, 23(6):1149-1152.
[10] BARRON S J, DEL VECCHIO M T, ARONOFF S C. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis:a meta-analysis with meta-regression of observational studies[J]. Int J Dermatol, 2015, 54(1):108-115.
[11] YAN A Z, FENG Z Q, CAI B S, et al. Nursing care of highdose glucocorticoid combined with immunoglobulin in the treatment of toxic epidermal necrolysis[J]. Diagn Ther J Dermatol-Venereol (皮肤性病诊疗学杂志), 2016, 23(2):122-124.
[12] PRINS C, VITTORIO C, PADILLA R S, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome:a retrospective, multicenter study[J]. Dermatology, 2003, 207(1):96-99.
[13] MOCKENHAUPT M. Stevens-Johnson syndrome and toxic epidermal necrolysis:clinical patterns, diagnostic considerations, etiology, and therapeutic management[J]. Semin Cutan Med Surg, 2014, 33(1):10-16.
[14] TOCCO-TUSSARDI I, HUSS F, PRESMAN B. Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center[J]. J Cutan Pathol, 2017, 44(5):420-432.
[15] VIVAR K L, DESCHAINE M, MESSINA J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy[J]. J Cutan Pathol, 2017, 44(4):381-384.
[16] PAVLOS R, MALLAL S, PHILLIPS E. HLA and pharmacogenetics of drug hypersensitivity[J]. Pharmacogenomics, 2012, 13(11):1285-1306.
[17] POURHASSAN H Z, TRYON D, SCHAEFFER B, et al. Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma[J]. Exp Hematol Oncol, 2019, 8:20.
[18] CHEN Q, HUANG D S, ZHANG L W, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma[J]. Clin Toxicol (Phila), 2018, 56(7):667-671.
[19] ZIMMERMAN J L, SHEN M C. Rhabdomyolysis[J]. Chest, 2013, 144(3):1058-1065.
[20] ZHAO S, GAO G, LI W, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer[J]. Lung Cancer, 2019, 130:10-17.
[21] PINATO D J, HOWLETT S, OTTAVIANI D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019, 5(12):1774-1778.
[22] CHEN W, SHAN K. Advance in Steven-Johnson syndrome and toxic epidermal necrolysisi[J]. Diagn Ther J Dermatol-Venereol(皮肤性病诊疗学杂志), 2019, 26(2):125-128.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
2019年湖南省自然科学基金科卫联合基金项目资助(2019JJ80019 )
{{custom_fund}}
PDF(4186 KB)
